Johnson & Johnson is committed to enabling equitable global access to the Janssen COVID-19 vaccine on a not-for-profit basis for emergency pandemic use, pending local regulatory authorizations and direct procurement agreements with governments. In December 2020, the Company entered into an agreement in principle in support of COVAX, the global procurement mechanism for COVID-19 vaccines. We expect to enter into an Advance Purchase Agreement (APA) that would provide up to 500 million doses of the Janssen vaccine to COVAX through 2022.
At this time, the Company is only negotiating with government bodies and supranational organizations (e.g., European Commission, African Union, Gavi/COVAX) at a central level for vaccine procurement or purchase. We are not working with or through third parties for vaccine access during the current emergency pandemic period. National governments may reach out to us directly with any procurement questions by contacting: [email protected].
Johnson & Johnson recognizes the role of the private sector in addressing the pandemic and, at a future date, we will inform stakeholders when other options for vaccine procurement become available.